iReckon: Simultaneous isoform discovery and abundance estimation from RNA-seq data by Mezlini, A. M. et al.
Method
iReckon: Simultaneous isoform discovery
and abundance estimation from RNA-seq data
Aziz M. Mezlini,1,2,3 Eric J.M. Smith,1 Marc Fiume,1 Orion Buske,1 Gleb L. Savich,4
Sohrab Shah,5,6 Sam Aparicio,5,6 Derek Y. Chiang,4 Anna Goldenberg,1,3
and Michael Brudno1,2,3,7,8
1Department of Computer Science, University of Toronto, Ontario M5S 2E4, Canada; 2Centre for Computational Medicine, Hospital for
Sick Children, Toronto M5G 1L7, Canada; 3Genetics and Genome Biology, Hospital for Sick Children, Toronto M5G 1L7, Canada;
4Department of Genetics, University of North Carolina, Chapel Hill, North Carolina 27599, USA; 5Department of Molecular Oncology,
BC Cancer Agency, Vancouver, British Columbia V5Z 1L3, Canada; 6Department of Pathology, University of British Columbia,
Vancouver, British Columbia V6T 2B5, Canada; 7Donnelly Centre, University of Toronto, Ontario M5S 3E1, Canada
High-throughput RNA sequencing (RNA-seq) promises to revolutionize our understanding of genes and their role in
human disease by characterizing the RNA content of tissues and cells. The realization of this promise, however, is con-
ditional on the development of effective computational methods for the identification and quantification of transcripts
from incomplete and noisy data. In this article, we introduce iReckon, a method for simultaneous determination of the
isoforms and estimation of their abundances. Our probabilistic approach incorporates multiple biological and technical
phenomena, including novel isoforms, intron retention, unspliced pre-mRNA, PCR amplification biases, and multimapped
reads. iReckon utilizes regularized expectation-maximization to accurately estimate the abundances of known and novel
isoforms. Our results on simulated and real data demonstrate a superior ability to discover novel isoforms with a signifi-
cantly reduced number of false-positive predictions, and our abundance accuracy prediction outmatches that of other
state-of-the-art tools. Furthermore, we have applied iReckon to two cancer transcriptome data sets, a triple-negative breast
cancer patient sample and the MCF7 breast cancer cell line, and show that iReckon is able to reconstruct the complex
splicing changes that were not previously identified. QT-PCR validations of the isoforms detected in the MCF7 cell line
confirmed all of iReckon’s predictions and also showed strong agreement (r2 = 0.94) with the predicted abundances.
[Supplemental material is available for this article.]
Accurate methods for RNA-seq data analysis are proving essential
for characterization of gene regulation and function, as well as
understanding development and disease (Lopezbigas et al. 2005;
Kim et al. 2008; Wang et al. 2009). The plethora of alternative
isoforms present for many human genes significantly extend the
repertoire of proteins, and this source of variation has been linked
to human disorders, including cancer (Shah et al. 2012). The iden-
tification of the full set of transcripts present in a tissue, especially
those present at low abundance, remains challenging. Tran-
scriptome analysis from RNA-seq data typically involves solving
two subproblems:
1. Identification of the set of isoforms present in the data, and
2. Estimation of the abundance of these isoforms.
The first problem is challenging due to the incomplete nature
of RNA-seq data, with only two (paired) short reads generated from
each fragment of RNA. The second problem is complicated by the
plethora of sequencing biases present within a typical RNA-seq
data set, including base content and location within the isoform,
as well as PCR amplification bias, which results in multiple reads
generated from a single original fragment.
Some of the earlier methods for RNA-seq analysis addressed
either the identification or the quantification problem. For
identification, methods such as TopHat (Trapnell et al. 2009) and
MapSplice (Wang et al. 2010) align raw sequencing reads to the
genome in ways that allow for the discovery of novel isoforms
and identification of alternative and aberrant splicing events.
For quantification, early methods simply counted the number of
fragments mapping to each input isoform to compute its abun-
dance. However, recent methods have significantly improved on
this and have allowed for the correction of many systematic
biases. One such problem is the interdependence of the assign-
ment of reads to isoforms and the expression of the genes. While
the assignment of a read to an isoform clearly changes the
abundance prediction of this isoform, the converse is also true:
The likelihood that a read was drawn from a particular isoform is
proportional to its expression. This problem can be elegantly
solved by using the expectation-maximization (EM) algorithm as
previously shown in Nicolae et al. (2011) and Li et al. (2010).
Here, reads are assigned to isoforms based on an initial estimate of
each isoform’s abundance, and the estimates are recomputed
based on the reads. This process is iterated until it converges. One
drawback of the EM-based approaches is overfitting: All isoforms
provided to the program are assigned a (possibly very low)
abundance, even if they are not expressed.
To prevent overfitting, some approaches, like Cufflinks
(Trapnell et al. 2010), rely on parsimony and identify the minimum
set of isoforms necessary to explain the observed read data and
then reconstruct their abundance. Alternatively, RQuant (Bohnert
and Rätsch 2010) uses regularized quadratic optimization to cor-
rect for various sequencing biases in the more global coverage
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signal. One recent approach (Feng et al. 2011) identified the im-
portance of solving the two problems simultaneously. Indeed, ac-
curate estimation of isoform abundance is extremely difficult if
not all isoforms are known, as the read pairs generated from un-
identified isoforms can affect the quantity estimation of known
ones. Abundance estimation can be used to inform isoform re-
construction: Incoherent abundances likely indicate that some
isoforms were missed by the reconstruction stage. In this context,
IsoInfer/IsoLasso (W Li et al. 2011) was the first tool to simulta-
neously solve both identification and quantification problems by
computing a large set of possible isoforms and then using LASSO
(Tibshirani 1996) to select a subset of these that best explain the
observed abundances.
In this article, we present iReckon, an algorithm for simul-
taneous isoform reconstruction and abundance estimation. To
our knowledge, our method is the first to combine maximum
likelihood–based abundance estimation with analysis of a large
number of feasible isoforms in order to allow for novel isoform
detection. While the large number of parameters would typically
lead to overfitting, our method is based on the regularized EM
algorithm (Li et al. 2005) with a novel, nonlinear regularization
penalty to eliminate isoforms with marginal support. This allows
for the quantification and discovery of novel isoforms even with
very low expression. To speed up this algorithm, we introduce
several computational heuristics. Additionally, our method is the
first to directly model several biological and technical phenomena,
including the presence of unspliced pre-mRNA, intron retention,
and PCR amplification bias. Supplemental Figure S1 summarizes the
key features of iReckon and compares these to other popular tools.
We have evaluated the performance of iReckon using both
simulated data, with a known ground truth, and using several real
Illumina RNA-seq data sets, where we explore the method’s ability
to recapitulate previously known human transcripts. Additionally,
we apply our method to two cancer transcriptomes and demon-
strate its ability to discover complex splicing patterns (confirmed
by QT-PCR) that are missed by other methods.
Results
In this section, we first present a brief outline of the iReckon algo-
rithm, with additional details presented in the Methods section. We
then evaluate the performance of iReckon on both simulated and
real RNA-seq data and compare it to three popular existing algo-
rithms, Cufflinks (Trapnell et al. 2010), SLIDE (J Li et al. 2011), and
IsoLasso (W Li et al. 2011). Finally, we use iReckon to explore the
transcriptomes of two breast cancer data sets—a patient sample re-
cently sequenced at the BC Genome Sciences Center (Shah et al.
2012) and the MCF7 cell line (accession no. SRX040504) (Sun et al.
2011).
iReckon algorithm overview
The iReckon workflow consists of three stages: (1) the identifica-
tion of all possible isoforms, (2) realignment of reads to these iso-
forms, and (3) the reconstruction of abundances of every putative
isoform. iReckon then reports isoforms with positive abundances.
These three steps are overviewed within the next three subsections.
Subsequently, we describe a visualization tool for transcriptomic
data that we have developed for use with iReckon or any similar
method. The details of the methods and models are described in
the Methods section, as are the running time and memory re-
quirements of iReckon.
Reconstruction of possible isoforms
The first step of iReckon is the identification of isoforms possibly
present within the sequenced sample. While iReckon will accept
a set of annotations, we also align all of the reads to the genome
using an algorithm that allows for split-mapping. We used TopHat
(Trapnell et al. 2009) for this task, though another tool could
be used instead. The alignments and the known isoforms are used
to generate the set of all observed and known splice junctions,
which in turn are used to construct splicing graphs (Heber et al.
2002) that represent the isoforms possibly present within the
sample. Note that the information about splice junctions can
help us determine most alternative splicing events (exon skip-
ping, alternative donor/acceptor sites, etc.), except intron re-
tention, which is discussed in Isoforms Reconstruction Model
Extensions in the Methods section. For each graph, we then
enumerate all paths from each of the possible transcription start
sites to the end sites. Each such path corresponds to an isoform,
and we further add isoforms corresponding to pre-mRNA and any
putative intron retention events detected by our intron retention
statistical model (see Isoforms Reconstruction Model Extensions).
The total number of paths through the splicing graph can po-
tentially be extremely large. In such rare cases, we prioritize the
splice sites based on the number of reads split-mapped across each
site and select up to 100,000 paths through the graph with the
highest support.
Realigning the reads
For each putative isoform, we extract its corresponding DNA se-
quence and realign the paired reads to the set of all possible iso-
forms. This step allows for the direct (without splitting) alignment
of each read and allows us to use more sensitive alignment tools,
resulting in having more reads correctly aligned. This step also
corrects for coverage biases near exon junctions due to alignment
difficulty. Note that each read pair can align not just to multiple
isoforms within a gene but also to multiple genes. Each pair is
assigned an initial affinity for each isoform to which it was aligned.
This affinity is based on the alignment score and the inferred insert
length (for details, see Alignments and Resulting Optimizations).
Isoform selection and abundances estimation
Finally, we simultaneously determine the set of isoforms present in
the data and estimate their abundances by using a regularized EM
algorithm on the set of possible isoforms. The standard EM algo-
rithm iteratively estimates the abundance of each isoform based on
the read pairs currently assigned to it, and then reallocates the pairs
to isoforms based on both alignment scores and the isoforms’ es-
timated expression levels. Because the allocation of reads to iso-
forms depends on their expression, the process needs to be iterated
multiple times until it converges. The standard EM algorithm
would assign most isoforms a positive (though possibly very low)
abundance. However, this is likely to lead to inaccuracies, espe-
cially in our case, as iReckon considers the space of all possible
isoforms, with most not expected to be present in the sample.
To balance between maximizing the likelihood of the data
and the simplicity (number of isoforms) in the model, we intro-
duce a regularization penalty. While the ideal objective would
be to directly penalize the number of isoforms (or parameters;
L0-norm) (McLachlan and Peel 2000), optimizing such an ob-
jective is computationally intractable, so the sum of the param-
eters (L1-norm, or LASSO) is commonly used as a regularizer.




in the Methods, this is not appropriate for abundances, so we
introduce a novel regularization penalty based on a concave
function. We also extend the standard EM algorithm to properly
handle PCR duplicates (see Accounting for PCR Duplicates). The
isoforms with positive estimated abundances at the convergence
of the regularized EM are considered present in the sample and are
reported by the algorithm.
Visualization
We have found visualization of the RNA-seq data essential during
the development of our method and validation of novel isoforms,
as well as an effective way to evaluate the tool’s performance. To
enable effective visualization we have developed an RNA-seq anal-
ysis plug-in within the Savant Genome Browser (Fiume et al. 2010,
2012). The RNA-seq Analyzer plug-in displays the reads aligned
to the genome, computes for each read the probabilities of iso-
form of origin (these are visualized by coloring the reads), and
visualizes the coverage signal for each isoform. A local version of
iReckon is also implemented within the plugin and allows iso-
forms reconstruction and abundances estimation from the reads’
alignments to a single selected gene. Figure 1 displays the in-
terface of this plugin, which can be downloaded from http://
savantbrowser.com.
Performance comparison on simulated data
Since there is no ground truth for any real transcriptomic data set,
simulating realistic RNA-seq data is a standard method for com-
paring RNA-seq tools. We generated an RNA-seq data set based on
known human isoforms, while also introducing various alternative
splicing events (see RNA-seq Data Simulation) and utilized it to
quantify the performance of iReckon and three other programs
that perform both isoform abundance estimation and novel tran-
script discovery: Cufflinks, IsoLasso, and SLIDE. We aligned the
simulated data with TopHat and gave the four methods the library
of all known human isoforms to use as a guide. To compare the
methods, we evaluate their recall (TP/(TP + FN); fraction of true
isoforms, known or novel, identified by the method), precision
(TP/(TP + FP); fraction of reported isoforms, known or novel,
that are correct), as well as abundance estimation accuracy. To
compute these measures, we consider transcripts with positive
abundance reported by each method. We separate isoforms into
high, medium, and low abundance, based on the simulated iso-
form abundance as a fraction of the total simulated data (>103,
103 > x > 53105, and <53105, respectively). These three
classes make up 5%, 69%, and 26% of all isoforms. In these re-
sults, we did not consider isoforms corresponding to unspliced
pre-mRNA as this is only discovered and estimated by iReckon.
Figure 1. Screen shot of Savant transcriptome analysis plug-in (RNA-seq Analyzer). (A) Track for the reference genome. (B) Track visualizing aligned
reads, with the color representing their isoform of origin probabilities. (C ) Known isoform annotation from UCSC. (D) The estimated coverage signal for
the various isoforms detected by iReckon. If two RNA-seq data sets are loaded, one can also view differences between abundances of each isoform in the
two data sets. Note that the blue isoform has an intron retention event (middle). Because this isoform corresponds to a non-negligible fraction of the
overall gene expression level, the failure to identify this event may lead to inaccuracy in quantifying the other isoforms. Additionally, iReckon identifies and
quantifies the canonical isoform (in red), the pre-mRNA (in yellow,) and an additional isoform with an alternative donor site (in green). (E) An alternative
view of the relative isoform abundances and proportions of reads assigned to each isoform are provided via pie charts. In B and E, black reads are those that
could not be assigned to any detected isoforms.
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Figure 2A shows a comparison of the four methods at isoform
discovery. iReckon achieves the highest recall and precision.
Figure 2B demonstrates the method’s ability to identify isoforms
depending on their level of expression. While all methods perform
better at high-abundance isoforms than low-abundance ones,
iReckon’s performance degrades the least of the four methods.
Notably, iReckon’s recall for novel low-abundance isoforms is three
times that of the other methods (solid section of the bar). This is
likely due to the fact that iReckon uses efficient regularization and
that isoforms with unambiguous evidence in the data are still
reported, even at low abundance. In contrast, all other methods
filter out isoforms using abundance thresholds. To compare the
power of the different methods at discovering novel isoforms, in
Figure 2C, the recall and precision are computed by only consid-
ering novel isoforms (novel simulated and novel found). iReckon’s
precision is ;200% higher and its recall is 50% higher than other
methods of identifying novel isoforms from RNA-seq data.
To evaluate the abundance estimation accuracy of each
method, we compared the predicted isoform abundance of each
correctly identified isoform to its true (simulated) abundance. We
computed, for each isoform, the abundance error as the ratio
between the true and predicted abundance estimates, larger over
smaller. Figure 3A demonstrates the abundance estimation ac-
curacy for each of the four methods depending on the error
threshold. Here iReckon clearly outperforms Cufflinks, SLIDE,
and IsoLasso across all three abundance classes and for all error
thresholds. The full data are presented as scatterplots in Sup-
plemental Figure S11. In terms of median per-isoform abun-
dance deviation (deviation = error  100%), iReckon outperformed
the other methods on high-, medium-, and low-abundance classes
with 8%, 14%, and 48% median deviation, respectively. Cufflinks,
the second-best method overall, had 18%, 20%, and 70% median
deviation on the same classes, and SLIDE has a median deviation
of 11% on the fewer high-abundance isoforms it discovers. iRe-
ckon thus demonstrated a significantly better global accuracy than
Cufflinks (P-value of 8.06 3 1018, Wilcoxon signed rank test). Box
plots associated with these results are presented in Supplemental
Figure S12.
Figure 3B shows each method’s recall based on the abundance
estimation error. In this case, an isoform is not considered pre-
dicted correctly if its abundance is misestimated beyond the given
error threshold. Here iReckon also greatly outperforms the other
methods, due to both its better overall recall and its higher abun-
dance accuracy.
Performance comparison with Illumina BodyMap2 RNA-seq
data
To further test the ability of iReckon to identify novel isoforms in
real RNA-seq data, we used an Illumina BodyMap2 muscle tran-
scriptome data set (NCBI SRA accession ERR030876), which con-
sisted of ;82 3 106 pairs of 50 bp-long reads. Starting with the
36,796 RefSeq human transcripts we left out 7842 random iso-
forms to be used for testing, while the remaining 28,242 isoforms
were provided to the RNA-seq analysis methods. While there are
novel isoforms that are present in any tissue, overall we expect a
large fraction of true transcripts within the RNA pool to be known.
To evaluate each of the methods, we computed precision as the
ratio of the previously known isoforms identified by each tool to all
of its predictions, and recall as the fraction of the left-out isoforms
that were predicted as present by each method. The results are
summarized in Figure 4A.
Overall, Cufflinks and SLIDE respectively identified 69,186
and 19,602 isoforms from the RNA-seq data, of which 17,072 and
5137 were known human transcripts (precision = 0.25 and 0.26).
IsoLasso identified 81,086 transcripts, of which only 4514 were
Figure 2. Ability of the different methods to discover simulated isoforms. Simulation contains 2533 known isoforms (provided to the methods) and
1006 novel isoforms (811 exon skips, 195 intron retentions). (A) Overall precision and recall for discovering simulated isoforms (known + novel). (B) Recall
for isoforms based on level of expression. (Hashed bars) Proportion of known isoforms; (solid bars) novel isoforms. While Cufflinks slightly outperforms
iReckon on discovery of known isoforms with high abundance, the results on low-abundance isoforms are reversed, and iReckon outperforms the other
methods at identification of all novel isoforms (size of solid sections of bars). (C ) Precision and recall for discovery of novel isoforms, as well as recall specific




known, corresponding to a precision of 0.06. iReckon, demon-
strated the highest precision (0.58), identifying 26,848 isoforms,
of which 15,623 were known. The 8554 isoforms that were not
provided to the tools were then used to evaluate the recall of
various algorithms at predicting novel isoforms. Note that we
do not expect all of these 7842 to be expressed within this
sample; however, an overall higher recall (at equal precision) is
indicative of better performance. iReckon identified 827 of these
isoforms (recall = 0.11) as present in the sample, followed by
Cufflinks with 771 (recall = 0.10), IsoLasso with 443 (recall =
0.06), and SLIDE with 207 (recall = 0.03). To further understand
the types of isoforms that are rediscovered by each method, we
plotted the number of rediscovered isoforms at each abundance
level (Fig. 4B). While the distributions are similar overall, iReckon
has the highest number of low-abundance isoforms, including
being the only method that predicts more than a handful of novel
isoforms with reads per kilobase per million mapped reads
(RPKM) < 102 and three times as many isoforms with RPKM <
101 as any other method.
Currently, iReckon does not predict novel start/end sites for
isoforms; however, it can accept a set of known start/end sites as
additional input. To evaluate the extent to which adding the
ability to predict novel start/end sites may improve performance,
we used the isoform start and end points that were predicted
by Cufflinks as input to iReckon. By use of this data, iReckon
reported 29,527 isoforms, of which 16031 are known (precision =
0.54), while rediscovering 1084 left-out isoforms (recall = 0.14).
Applications of iReckon to cancer transcriptomes
After validating the performance of iReckon on both simulated
and real data, we used it to evaluate the splicing patterns in two
cancer transcriptomes, especially to validate the method’s ability
to identify intron retention events. The two transcriptomes we
consider are a triple-negative breast cancer (TNBC) patient sample
recently sequenced at the BC Genome Sciences Center (Shah et al.
2012) and the MCF7 cell line (NCBI SRA accession SRX040504)
(Sun et al. 2011). For comparative purposes, we also ran iReckon on
additional data sets from the Illumina BodyMap2 data set, in-
cluding muscle, brain, leukocytes, and breast. First, we evaluated
the total amount of expressed pre-mRNA and intron retention
identified in the various data sets, as well as the total number of
novel isoforms (Table 1). While the total amount of intron re-
tention or number of novel isoforms does not vary in a consistent
fashion, the total amount of pre-mRNA observed was higher in
the cancer transcriptome than in healthy tissues. This is generally
supported by previous literature indicating overall inefficient
splicing in some subtypes of cancer (Yoshida et al. 2011); however,
variation in experimental protocols, cell subtypes, and inter-
individual variation cannot be easily excluded either.
In the following sections, we consider two intron retention
events that have previously been reported in the cancer tran-
scriptomes: the last intron of the NPC2 gene in the MCF7 cell line
(Singh et al. 2011) and the seventh intron of the TP53 in the TNBC
sample (Shah et al. 2012).
Figure 3. Abundance estimation accuracy and isoform detection recall depending on the acceptable error threshold. (A) Abundance estimation
accuracy for correctly predicted isoforms. The three plots show the fraction of correctly estimated isoforms depending on the acceptable error rate
(isoforms with error above threshold have incorrect abundances) for high-, medium-, and low-abundance isoforms. While performance is best for high-
abundance isoforms for all methods, iReckon outperforms other methods for all three categories and regardless of the error threshold. (B) Isoform
detection recall depending on the acceptable error rate (isoforms with error above the threshold are considered ‘‘not predicted’’). iReckon outperforms the
other methods, especially for low-abundance isoforms.




In the study of Singh et al. (2011), the investigators identified and
validated an intron retention event as well as an exon skipping
event in the NPC2 gene. By running iReckon on this data set, we
were able to detect both of these events, each of which is present
in high abundance. RNA-seq reads alignment visualization with
Savant and iReckon plugin (Fig. 5) confirms the findings. Fur-
thermore, iReckon identified two additional alternative donor
sites, leading to two novel isoforms: one alternative site within the
exon, and one in the downstream intron. By use of the visualiza-
tion plugin, we also detected a previously unknown single nucle-
otide variant (SNV) in the first nucleotide of the intron’s donor site,
changing the canonical GT to AT. The intron retention, the exon
skipping, or the two alternative donor sites were not present in the
TNBC data sets or in the Illumina healthy breast data set, and none
of the events were found in the NCBI EST library. Thus, it is likely
that the disruption of the canonical donor site of the last intron of
the NPC2 gene results in several types of noncanonical splicing,
including the following:
1. Intron entirely retained, resulting in an aberrant isoform;
2. Use of an alternative intra-exonic donor site 9 nucleotides (nt)
upstream, resulting in the deletion of three amino acids from
the coding region;
3. Use of an alternative donor site 16 nt downstream, resulting in
an out-of-frame aberrant isoform; and
4. The skipping of the whole exon preceding the disrupted donor
site, indicating that the splicing machinery failed because of
unsuccessful exon recognition, rather than intron recognition
(Berget 1995). The resulting mRNA product is also out-of-frame.
Table 2 presents the abundances of each of these isoforms, as
well as the number of reads that can be uniquely assigned to each
isoform.
To validate iReckon’s results, we performed QT-PCR with
primers designed to detect each of the four isoforms (as well as the
canonical one). All four isoforms were confirmed by QT-PCR, while
the abundances observed closely matched those predicted by
iReckon (see Table 2; r2 = 0.94). The homozygous SNP that we
detected disrupting the donor splice site (Fig. 5) was also confirmed
by Sanger sequencing. For comparative purposes, we also ran
Cufflinks and IsoLasso on this data set (we encountered technical
issues with SLIDE) and noted that each of these methods missed
two out of four novel isoforms (and predicted no additional ones).
TNBC transcriptome
While the MCF7 cell line consists exclusively of tumor cells, the
TNBC transcriptome was taken from a patient biopsy and thus
consists of a mixture of healthy and tumor material. Previously,
Shah et al. (2012) uncovered a mutation in the acceptor site of
intron 7 of TP53, mutating the canonical AG to GG and observed
a correlated increase in the retention of the subsequent intron
(computed using Miso) (Katz et al. 2010). The initial interpretation
was that the mutation led to mis-splicing of the intron, leading to
its retention.
We evaluated this data set with iReckon and, surprisingly, did
not predict the retention of intron 7. Instead, our method reported
a significant presence of pre-mRNA, an alternative acceptor site
used 19 bp downstream, as well as complete skipping of exon 8. All
three of these events were found only in the TNBC data set and not
in the healthy Illumina BodyMap2 breast or the MCF7 sample.
These isoforms are shown in Figure 6.
Figure 4. (A) The precision of the four methods at identifying known genes and their recall for discovering novel (hidden) isoforms from Illumina RNA-
seq data. (B) Histogram of the abundances of hidden isoforms (re-)discovered by each method. The x-axis units are log (RPKM).
Table 1. Expression of pre-mRNA and isoforms with retained
introns, and the number of novel transcripts in Illumina BodyMap2
healthy muscle, brain, leukocyte, and breast tissues, as well as
a triple-negative breast cancer biopsy and the MCF7 cell line
Muscle Brain Leukocytes Breast TNBC MCF7
Pre-mRNA 3,392 6,101 2,855 5,131 7,556 7,777
Intron retention 7,469 10,552 10,791 8,443 9,858 9,227
No. of novel
isoforms
15,598 23,606 14,027 20,131 18,685 24,787




These results show that the consequences of a mutated ac-
ceptor site disruption are more complex than simply retaining the
intron, and include the following:
1. An alternative intra-exonic acceptor site 19 nt downstream
from the canonical site being used, creating an out of frame
aberrant isoform.
2. The acceptor site of the next intron being used, resulting in
exon skipping. The skipped exon length is not a multiple of
three and creates an out of frame aberrant isoform.
3. The entire splicing mechanism becomes disrupted or slowed,
resulting in the large abundance of partially spliced pre-mRNA
with all four final introns retained in the transcript. If we con-
sider the isoform corresponding to pre-mRNA and divide it into
three segments, corresponding to in-
trons 1–6, intron 7, and introns 8–10,
the abundance estimates for these are
0.3, 2.4, and 2.5 RPKM, respectively.
The coverage of the last four introns is
thus consistent with disruption of
splicing after the mutation, rather than
the retention of a single intron.
Table 3 summarizes the abundances
of these isoforms and the number of
reads unambiguously mapped to each. All
three events were only seen in the TNBC
data set with this specific mutation and
not in healthy breast or the MCF7 cell
line. We expect TP53 mutations in TNBC
to be early events in the evolutionary history of the tumor and
therefore to be present in all (or the majority of) cells; however, the
presence of multiple isoforms could result from either multiple
aberrant transcripts within each cell, or the presence of multiple
clonal populations in the sample. The relative quantity of TP53
pre-mRNA was higher in TNBC than in healthy breast and MCF7
(5.7% vs. 0.9% and 1.6% of the gene expression, respectively). Fi-
nally both the alternative acceptor site and the exon skipping
event have not been previously reported in the NCBI EST library.
Discussion
In this article, we introduce iReckon, a method for simultaneous
isoform discovery and abundance estimation. iReckon models
Table 2. Summary of detected isoforms of NPC2 in the MCF7 data set
iReckon results Relative abundances
Isoform
Abundance
(RPKM) Evidence iReckon QT-PCR Cufflinks isoLasso
Intron 4 retention 47.9 >200 38% 37% 0% 30%
Exon 4 skipping 51.7 120 41% 35% 37% 70%
Alternative donor site within exon 4 6.3 19 5% 13% 0% 0%
Alternative donor site within intron 4 20.1 41 16% 15% 63% 0%
Canonical (NM_006432) 0 0 0% 0% 0% 0%
Evidence is the number of read pairs (not counting duplicates) uniquely mappable to the corre-
sponding isoform and no other found isoform. The four last columns are the relative abundances within
the NPC2 gene measured by iReckon, QT-PCR, Cufflinks, and IsoLasso.
Figure 5. Screen shot of Savant displaying a segment of the NPC2 gene in the MCF7 data set. (Red isoform) Exon skipping; (blue) intron retention;
(green and yellow) contain the two alternative donor sites. The purple isoform with low expression is the pre-mRNA.
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important biological phenomena such as intron retention and the
presence of pre-mRNA. Our method generates a large set of possi-
ble isoforms and then utilizes a regularized EM algorithm to select
expressed isoforms from these. Due to this particular approach and
to the modeling of several RNA-seq artifacts (multimapping reads,
PCR duplicates, biases) and biological mechanisms (pre-mRNA,
intron retention), iReckon outperforms three popular current
methods—Cufflinks, IsoLasso, and SLIDE—at both the identifica-
tion of novel isoforms and the estimation of isoform abundances.
We utilized iReckon to analyze the complexity of splicing profiles
generated by the disruption of two canonical splice sites in a TNBC
patient biopsy sample and the MCF7 cell line. In particular, we
observed three or more different aberrant isoforms generated for
both genes considered. The observed complexity of the splicing
landscape raises important questions about the mechanisms in-
volved and may lead to a better understanding of the underlying
biology. The ability of iReckon to identify intron retention and pre-
mRNA abundance may allow for novel biological discovery, for
example, the pre-mRNA signal can be used to discern splicing or-
der, as introns that are spliced-out later will be overrepresented in
the pre-mRNA. Similarly, the analysis of intron retention can help
uncover somatic mutations in cancer by identifying genes prone to
aberrant splicing.
Finally we want to note that while iReckon outperforms other
tools, there is still significant room for improvement. Even with
simulated data, the top competing methods achieved overall recall
of 62%, compared with 74% for iReckon; however, the numbers
dropped significantly when one considers only novel isoforms: to
41% and 58%, respectively. Thus, nearly half of all novel isoforms
are not being identified. Several steps can be taken to further im-
prove the performance of iReckon. Perhaps the most important
one is incorporation of sequencing biases, including those based
on sequence content (e.g., GC rate) and location of a read within
an isoform. Additional improvements can be achieved by directly
modeling a wider variety of biological events. One such event,
which may prove to be especially challenging, is the identification
and abundance estimation of fusion genes. The performance of
iReckon will also improve with development of better split-read
mapping algorithms. Many of iReckon’s false-negative isoforms
Figure 6. Savant screen shot showing healthy breast (from Illumina BodyMap2) and triple-negative breast cancer RNA-seq data. The third and fourth
tracks display the aligned reads from healthy and cancer tissue, respectively, with the colors representing the isoform of origin. (Red isoform) Canonical
annotated isoform. Its presence may be due to healthy cells biopsied together with the tumor. (Green isoform) Pre-mRNA (or partially spliced RNA);
(blue) contains the alternative acceptor site; (yellow) skips the next exon (to the left since the transcript is on the reverse strand). We can also see the single
nucleotide variant (SNV) that disrupted the acceptor site of the intron.










Exon 8 skipping 0.9 5 5.9%
Canonical (NM_000546) 10.6 25 73.1%
Evidence is the number of read pairs (not counting duplicates) uniquely




in the simulation experiments (especially unidentified exon-skip-
ping) were caused by splice junctions undiscovered by the initial
alignment step.
Methods
Isoform reconstruction model extensions
In addition to modeling novel isoforms via paths in the splicing
graph, as described in the Results section, iReckon also allows for
two additional types of isoforms: pre-mRNA and isoforms with
a retained intron.
Incorporating pre-mRNA
In real RNA-seq data, we observed that ;1%  30% of the RNA
content for each gene can be due to unspliced pre-mRNA. While
the exact percentage will vary due to gene regulation and sequence
content, it is clear that treating pre-mRNA as noise can bias the
results by leading to overestimation of isoform abundances (since
some of the reads originally coming from pre-mRNA will be as-
signed to other isoforms) and can further complicate isoform
reconstruction due to reads mapping across splice sites and into
introns. To address this problem we add the complete pre-mRNA as
a potential isoform for each gene predicted from the original re-
construction. This (unspliced) isoform’s abundance is computed in
the exact same manner as that of all other isoforms. Because these
isoforms are only reported by our method, we do not consider
these when evaluating the accuracy of the various tools.
Intron retention model
Incomplete pre-mRNA splicing can lead to intron retention events,
where certain introns remain within mRNA that has undergone
splicing. Transcripts with unspliced introns may affect cell func-
tion due to malformed proteins or haplo-insufficiency. Such intron
retention events have been shown to play a role in certain cancers
(Skotheim and Nees 2007; Kim et al. 2008; He et al. 2009). Note
that intron retention cannot be accurately estimated if we do not
take pre-mRNA into account, as reads from introns can be ex-
plained by either unspliced mRNA or intron retention.
We consider the null hypothesis H0, that there is no intron
retention, and all reads within introns come from unspliced pre-
mRNA. To compute the P-value, we start by estimating the pre-
mRNA abundance as the average coverage of introns. The isoform
coverage signal at a nucleotide can be modeled by a Poisson(l)
distribution with the Poisson parameter being the average cov-
erage (read locations are often modeled as Poisson variables, and
the sum of Poisson variables is also Poisson). We compute the
l parameter for the pre-mRNA of each gene and reject the null
hypothesis and detect an intron retention if an intron’s coverage
is statistically unlikely to be generated from the pre-mRNA
(P-value < 104). Intron retention is a relatively rare event, so to
reduce the computational complexity, iReckon considers only
the one intron with the lowest P-value retained per gene. If
we detect intron retention within a gene, we generate, for each
isoform, a novel putative isoform with the corresponding intron
retained within the mRNA and pass all these isoforms to the
regularized EM algorithm.
Alignments and resulting optimizations
After constructing the set of all possible isoforms, we store their
sequences in a transcriptome reference file (as opposed to a ge-
nome reference). We then use Burrows-Wheeler alignment (BWA)
(Li and Durbin 2009) to align all the reads to the transcriptome,
and from the possible alignments, we can compute read-isoform
affinities for the nth read pair and the ith isoform as
An;i = Q n; ið Þ  L length n; ið Þð Þ; ð1Þ
where Q(n, i) is the mapping probability of the nth pair to the ith
isoform computed from the alignment scores, L is the probability
density function of the fragment length distribution within our
RNA-seq experiment, and length(n,i) is the length of the fragment
corresponding to the nth read pair if it originated from the ith
isoform. These affinities are related to the compatibilities of Li et al.
(2010) and Nicolae et al. (2011). The probability that the nth read
pair, which aligns to the set of isoforms Sn, comes from the specific
isoform of index i, of normalized abundance ui is computed as
follows:




+j2Sn An; j  uj
: ð2Þ
Zni is an indicator latent variable that is one if read pair n was
generated from isoform i, and zero otherwise, and its expected
value is E[Zni] = P(Zn,i = 1).
Additionally, to improve the running time of the subsequent
step, we separate all isoforms into independent groups, such that
no read is mapped to isoforms in more than one group. Each of
these groups can be processed separately by the regularized EM
algorithm presented next, allowing for simple parallelizations
and reducing memory usage. To further optimize the algorithm,
we cluster the reads by their affinity signature. All the reads that
align to the same subset of isoforms with very similar relative read–
isoform affinities are clustered together and assigned to isoforms as
a single entity, so that our algorithm only considers the affinities
and cardinality of each cluster, instead of evaluating each read
independently. We use a simple greedy clustering algorithm that
unifies all pairs within a fixed distance of the center of the cluster.
This heuristic has no observed influence over the performance of
iReckon (recall, precision, quantification accuracy) while greatly
improving its speed and reducing its memory usage. For clarity
of presentation, we consider each read pair separately in the for-
mulae below.
Regularized EM algorithm
Our method is an extension of previous EM-based approaches for
transcript quantification (Li et al. 2010; Nicolae et al. 2011). The
likelihood function for transcript abundance estimation with
multimapped reads is very similar to the one introduced by Li et al.
(2010):









 P rnjiso = ið Þ
 
: ð3Þ
Here r = (r1, r2,. . ., rN) is the set of read-pairs and l = (l1, l2,. . ., lM),
u = (u1, u2,. . ., uM) are, respectively, the lengths and abundances
of the isoforms. zn,i is the value of the Zn,i latent indicator variable
(see Equation 2). Finally, P(rn|iso = i) is the probability that the read
rn is sampled from isoform i, and is constant with respect to the
abundances u.
As discussed previously, this algorithm may suffer from over-
fitting. Because not all isoforms are expressed in a given sample,
this problem is present even if only known isoforms are consid-
ered (Nicolae et al. 2011) and is exacerbated if the algorithm
considers putative novel isoforms, most of which are likely to
be false positives (Feng et al. 2011). Additional (unmodeled)
biases and noise in the RNA-seq data further confound this, as
extraneous predictors (isoforms) will be used to fit the noise and
biases to increase the overall likelihood. Because our algorithm
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considers all plausible isoforms, it becomes crucial to introduce
efficient regularization to remove false-positive isoforms by driv-
ing their expression to zero.
While the L1 penalty is commonly used as a solution to
overfitting (e.g., Tibshirani 1996), it is not appropriate for abun-
dance estimation. Because isoform abundances (in RPKM) are sim-
ilar to normalized frequencies, they have positivity constraints as
well as a fixed sum (see definition of RPKM):
+
i
ui  li = C;0 # ui 8i: ð4Þ
The constant C is discussed in section 5 of the Supplemental
Information. The regularization term minimized by LASSO is the
sum of the abundances. However this term is tightly constrained,
because abundances are very similar to frequencies. This type of
regularization is not adequate in the hyperplane of the u vari-
ables (described by the constraints). In order to reduce the
number of nonzero abundances and thus avoid overfitting, we
use a nonlinear function of the abundances in the penalty term.






ficiency in giving sparse solutions (the fourth root is steep near
zero) and its fast convergence speed. The specific shape of the
function heavily penalizes low-abundance isoforms, while the
penalty for high-abundance ones is lower. Adding regularization
to the EM algorithm requires changes to the M step, as we
can no longer directly solve the maximization problem. Hence
we use a limited-memory Broyden–Fletcher–Goldfarb–Shanno
(LBFGS) (Zhu et al. 1997) optimization algorithm for the M step,
and because the objective function is no longer concave, we
utilize random restarts to allow the EM algorithm to more fully
explore the search space. The regularization rate l is set so that
most read pairs have affinity to an isoform with positive abun-
dance. To do so, we iteratively increase lambda using pro-
gressively smaller steps until growing it any further would result
in >0.01% of all reads not being assigned to an expressed isoform.
We compared the performance using our regularization term,
LASSO, and not doing regularization at all, and show that LASSO
is inappropriate, while our method outperforms not doing reg-
ularization for most genes (see section 3 of the Supplemental
Information).
The log-likelihood function that we optimize through the
regularized EM algorithm is as follows:





+ coherenceScore uð Þ; ð5Þ
where the first term is the data log-likelihood described above
(with modifications to account for PCR Duplicates, described in
the next section) and the second term is the regularization penalty.
The third term (coherence score) is described fully in section 4 of
the Supplemental Information. It is an additional parameter that
allows the algorithm to further differentiate between multiple so-
lutions with nearly identical likelihoods (for a full description of
the isoform reconstruction ambiguity problem, see Lacroix et al.
2008). Because the regularization term deforms the final solution
(abundances tend to become lower), our implementation contains
a second step where we re-run the EM algorithm without regula-
rization using only the isoforms with positive abundance in the
optimal solution of Equation 5.
Accounting for PCR duplicates
Multiple rounds of PCR during the RNA-seq experiment can lead to
multiple identical read pairs being generated from the same frag-
ment. Either systematically removing or keeping all duplicates will
bias the results. For example, in highly expressed genes, the ob-
served duplicate reads may be natural duplicates (read pairs with
identical locations generated from independent fragments), and
removing them will cause underestimation of abundances. We
estimate, for each read, its likelihood of being a PCR duplicate and
use this probability in the objective function of the EM algorithm
presented earlier (Equation 3).
First, we compute for each isoform the number of expected
natural duplicates. Given an isoform with a known length l and
abundance a, one can estimate the number of read pairs w that will
be generated from this isoform. We treat w as the number of samples
(fragments) drawn from the isoform. We estimate the probability
pf of a specific fragment f based on the isoform length, the fragment
length distribution, and any biases (normalizing so that the prob-
abilities of the different possible fragments sum to 1). The number of
occurrences Xf of that particular fragment f is modeled by a binomial
distribution B(w, pf), which can be approximated by the Poisson (w 3
pf) distribution since w is usually large (>20) and pf is very small
(<0.01). The number of duplicates of f is represented by the random
variable Yf = max{0, Xf 1} corresponding to one ‘‘original read’’ and
Xf  1 copies. Yf has the expected value
E Yf
 
= pf w + epf w  1: ð6Þ
The derivation of this equation is presented in the Supplemental
Information. The total expected number of natural duplicates is
the sum of the expectations over the possible fragments:








where Fs is the set of fragments starting at position s that can
possibly be originated from the studied isoform.
For each read rn, we now calculate the probability P(dn = 1),
dn being the indicator variable that is zero when the read is a
PCR duplicate. For the ith isoform, let Nb_Copiesi be the observed
number of duplicates and Nb_Naturali the number of expected
natural duplicates (computed in Equation 7). Then
P dn = 1ð Þ =
minf+i2Sn E Zni½ Nb Naturali+i2Sn E Zni½ Nb Copiesi if the n
th read is a copy




where Sn is the set of isoforms the read rn aligns to, and E[Zni] is the
alignment probability based on Equation 2. The EM likelihood
function presented earlier (Equation 3) can thus be updated to
properly account for PCR duplicates by adding the indicator vari-
able dn:
log P r; z; d j uð Þ= +
n;i
dn  zni  log
ui
li
 P rn j iso = ið Þ
 
: ð9Þ
Because small changes in abundances do not significantly affect
duplicate estimation, we do not need to update the E[dn] proba-
bilities at every iteration of the EM algorithm. For efficiency, we
update these only when the abundances have changed signifi-
cantly from their previous values.
RNA-seq data simulation
To simulate a realistic data set with known ground truth, we ran-
domly selected 75% of the multi-exonic isoforms of the UCSC
refGene data set to study and, for each of these, generated a set of
alternative splicing events: exon skipping and intron retention.
Each exon had 10% chance to be skipped, and the skipping could
be extended to the following exons with 30% probability per
exon, while each intron was retained with 1.8% probability. These




gene and based on the number of alternative isoforms already
simulated. We then selected multiple random subsets of all events
to be implanted in the original isoform. Finally, we add to this set
of isoforms the pre-mRNAs of all studied genes.
This set of isoforms is then given to FluxSimulator (The
FluxProject 2011), which randomly orders these and picks an
abundance for each following a mixed power/exponential law.
The parameters from the law were chosen so that the range of the
isoforms’ expression is 104 (the highest abundance over the lowest).
While FluxSimulator assigned a random abundance to the pre-
mRNA, we adjusted this to 10% of the initial value to correspond to
the expected low abundance of such isoforms. FluxSimulator was
then used to simulate RNA-seq read pairs from these isoforms in
a manner that reproduces in silico the experimental pipelines for
RNA-seq, making the simulated data sets as realistic as possible.
The results presented here are obtained from a simulation
with 1615 genes, 8 million read pairs, and 3539 isoforms, of which
30% are novel (pre-mRNAs are not counted). We also conducted
three additional simulations with slightly different parameters
(number of reads, proportion of novel isoforms, etc.), but no sig-
nificant change was observed in the results of the comparison
between iReckon and the other methods (data not shown).
Program performance
iReckon required 22 h to complete on the Illumina BodyMap2
muscle data set (contains ;82 3 106 pairs of 50-bp-long reads),
using an eight-core machine with 32-GB RAM (the actual memory
usage maxed at ;9 GB) and 80 GB of local storage. The largest
component of the running time (10 h) is the alignment of reads to
isoforms using BWA.
Software availability
iReckon is available both as a standalone package (open source),
which can be downloaded from http://compbio.cs.toronto.edu/
ireckon, and as a plugin for the Savant Genome Browser (Fiume
et al. 2010, 2012), which enables running iReckon on individual
genes in real-time.
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